Call (818) 262-3537 · Available 24/7 · 100% confidential
Dual Diagnosis Meth Treatment in Los Angeles
IntegratedFrom Intake Forward
PsychiatricMedication Management
SAMHSA-Recommended Model
CARFBehavioral Health Accreditation
Medically reviewed by Vinsent Franke · Last updated June 25, 2026
INTRO
Most people with meth addiction also have a co-occurring mental health condition: depression, anxiety, bipolar disorder, PTSD, or trauma. Treating one without the other is the most common cause of relapse. Meth temporarily numbs psychiatric symptoms while making them significantly worse over time, and untreated mental illness drives the meth use to start with. Sequential treatment, addiction first, mental health later, has decades of evidence showing it does not work as well as integrated dual-diagnosis care.
At iRely Recovery in Los Angeles, dual diagnosis meth treatment is integrated from intake. Both conditions are assessed and treated in parallel through the Matrix Model, contingency management, CBT, and psychiatric medication management when clinically appropriate.
Why Integrated Treatment Matters for Meth
The clinical pattern is consistent across stimulant use disorder: untreated psychiatric conditions are the single largest driver of meth relapse, and untreated meth use is the single largest barrier to mental health symptom improvement. Treating them sequentially, sober up first, then address the depression or PTSD, leaves the underlying drivers of substance use untouched during the period when relapse risk is highest.
Integrated dual diagnosis treatment addresses both at once. Clinicians coordinate medication management with substance use treatment, individual therapy targets both conditions simultaneously, and group work addresses the patterns that link them. Research from SAMHSA and the National Institute on Drug Abuse consistently shows integrated treatment produces better retention, fewer relapses, and better mental health outcomes than sequential care.
Conditions We Treat Alongside Meth
Several specific co-occurring conditions appear repeatedly in meth recovery, and iRely Recovery has dedicated treatment pathways for each:
Depression — meth depletes the dopamine systems responsible for pleasure and motivation, and depression is one of the most common acute and post-acute consequences. See meth and depression treatment.
Anxiety and paranoia — stimulant-driven anxiety and meth-induced paranoia respond to specific integrated treatment combining medication, CBT, and mindfulness. See meth and anxiety treatment.
Bipolar disorder — the mania overlap between bipolar episodes and meth highs requires careful diagnosis and medication stabilization. See meth and bipolar treatment.
PTSD — the PTSD-stimulant loop is well-documented; trauma-focused therapy combined with stimulant treatment is essential. See meth and PTSD treatment.
Complex trauma — unresolved trauma often drives self-medication with stimulants; somatic and trauma-focused care addresses the root. See meth and trauma treatment.
Integrated assessment in your first call.
iRely’s Integrated Dual Diagnosis Model
Integration is structural at iRely Recovery, not bolted on. Initial assessment screens for both substance use disorder and co-occurring psychiatric conditions, psychiatric medication management is coordinated with substance use treatment from intake, individual therapy targets both conditions in the same sessions, and group work addresses the patterns linking them.
Therapeutic modalities include the Matrix Model intensive outpatient program, contingency management, CBT for meth addiction, trauma-informed somatic therapy, EMDR when indicated, and ongoing psychiatric care. For a broader view of how iRely treats dual diagnosis across all substances, see our general dual diagnosis program.
The Order of Treatment: Detox to Stabilization to Integrated Care
For dual diagnosis clients, the sequence of care matters but the principle of integration is constant throughout. When medically necessary, medically assisted detox stabilizes acute withdrawal and medical concerns first. Residential or inpatient care follows when psychiatric or medical stabilization requires a higher level of support.
Throughout detox and residential phases, psychiatric assessment and medication management are coordinated alongside substance use treatment, not deferred. Intensive outpatient (the Matrix Model) follows, with the same integrated clinical team continuing both substance use and psychiatric care. Aftercare and alumni support maintain the integration long-term. Most major insurance plans cover dual diagnosis treatment under behavioral health benefits required by federal parity laws; we verify in 5 to 10 minutes.
Dual Diagnosis Meth Treatment FAQ
What is dual diagnosis treatment?
Dual diagnosis treatment is the integrated clinical care of co-occurring substance use disorder and mental health conditions in the same treatment plan, by the same clinical team, at the same time. For meth specifically, this means treating both the stimulant use disorder and the underlying or co-occurring depression, anxiety, bipolar disorder, PTSD, or trauma simultaneously rather than sequentially. SAMHSA-recommended.
Why treat meth and mental health together?
Because sequential treatment does not work as well. Untreated mental illness drives meth relapse during the period when relapse risk is highest. Meth use prevents mental health symptoms from improving and accurate diagnosis from happening. Research from SAMHSA and NIDA consistently shows integrated dual diagnosis treatment produces better retention, fewer relapses, and better mental health outcomes than addressing the two conditions in sequence.
What conditions do you treat alongside meth?
iRely Recovery treats meth alongside depression, anxiety, paranoia, bipolar disorder, PTSD, and complex trauma as our most common dual diagnosis configurations. Each has a dedicated treatment pathway with specific therapeutic modalities. Additional psychiatric conditions are assessed and treated as needed; our admissions team can discuss your specific situation in a confidential intake call.
Does insurance cover dual diagnosis?
Yes. Dual diagnosis treatment is covered by most major insurance plans under behavioral health benefits required by federal parity laws (Mental Health Parity and Addiction Equity Act). iRely Recovery is in-network with most major carriers. We verify coverage in 5 to 10 minutes. Start a verification here.
How long does dual diagnosis treatment take?
Treatment length is personalized to clinical need. The Matrix Model intensive outpatient core runs about 16 weeks, often preceded by medically assisted detox or residential care when clinically indicated. Dual diagnosis often benefits from longer engagement than minimum stimulant-only treatment because both conditions require sustained therapeutic work and medication stabilization.
Is medication used in dual diagnosis treatment?
Yes, when clinically appropriate. iRely Recovery provides psychiatric medication management for co-occurring conditions throughout treatment, coordinated with substance use care. There is no FDA-approved medication specifically for methamphetamine use disorder, but psychiatric medications for depression, anxiety, bipolar disorder, and PTSD are well-established and often essential for dual diagnosis recovery.
Get Integrated Dual Diagnosis Care
Both conditions, one coordinated treatment plan, from intake forward. Get a confidential conversation about iRely Recovery’s integrated dual diagnosis meth program in Los Angeles.
Available 24/7 · 100% confidential
Sources
[1] Substance Abuse and Mental Health Services Administration. Co-Occurring Disorders and Other Health Conditions. SAMHSA. https://www.samhsa.gov/medications-substance-use-disorders/medications-counseling-related-conditions/co-occurring-disorders Retrieved June 28, 2026.
[2] National Institute on Drug Abuse. Common Comorbidities with Substance Use Disorders. NIDA. https://nida.nih.gov/research-topics/comorbidity Retrieved June 28, 2026.
[3] National Institute on Drug Abuse. Methamphetamine. NIDA. https://nida.nih.gov/research-topics/methamphetamine Retrieved June 28, 2026.
[4] Methamphetamine. StatPearls; National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK535356/ Retrieved June 28, 2026.
